Posted by Michael Wonder on 01 Feb 2023
Upadacitinib monohydrate for the treatment of patients with active non-radiographic axial spondyloarthritis
1 February 2023 - Upadacitinib monohydrate is recommended as an option for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs).
It is recommended only if:
- Tumour necrosis factor (TNF) alfa antagonists are not suitable or do not control the condition well enough and
- AbbVie provides upadacitinib monohydrate according to the commercial arrangement
